Mayer Brown advises SERB Pharmaceuticals and its majority shareholder Charterhouse Capital Partners on the structuring of the acquisition of RSDL® (Reactive Skin Decontamination Lotion)

Mayer Brown advises SERB Pharmaceuticals and its majority shareholder Charterhouse Capital Partners on the structuring of the acquisition of RSDL® (Reactive Skin Decontamination Lotion) from Emergent BioSolutions Inc. (NYSE: EBS). RSDL® is a medical device produced as a kit that removes or neutralizes chemical warfare agents from the skin.